Shanghai Pharma raises $2 billion from Hong Kong listing

China's second-biggest drug distributor prices its H-share offering below the mid-point, but at a modest 2.4% discount versus its A-shares.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES